The safety of biologic therapies in RA-associated interstitial lung disease.

doi:10.1038/nrrheum.2013.197

PMID: 24366321DOI: 10.1038/nrrheum.2013.197Dec 25, 2013Paper

The safety of biologic therapies in RA-associated interstitial lung disease.

Nature Reviews. Rheumatology

Meghna JaniW G Dixon

Abstract

Interstitial lung disease (ILD) is a common extra-articular manifestation associated with increased morbidity and mortality in patients with rheumatoid arthritis (RA). Early case reports of serious respiratory adverse events (SRAEs) following treatment with anti-TNF agents have led to concerns about biologic therapy in patients with RA-associated ILD (RA-ILD), and a tendency for biologic agents targeting factors other than TNF to be prescribed in such patients. At present, the appropriateness of such decisions is not clear. Given that the therapeutic goal for RA is remission, clinicians increasingly face the challenge of choosing the optimal biologic agent in patients with RA-ILD and uncontrolled joint disease. However, no evidence-based guidelines exist to guide physicians in deciding whether to commence biologic therapy in this setting, or in selecting which drug is most appropriate. Herein, we review the evidence for the comparative pulmonary safety of anti-TNF agents and non-TNF-targeting biologic agents in RA-ILD. In addition, we propose a framework for assessment of baseline disease severity to guide treatment decisions, and for monitoring during therapy. Because of substantial gaps in the available evidence, we also desc...Continue Reading

References

Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha

Dec 1, 1995·American Journal of Respiratory and Critical Care Medicine·Y KapanciG Gabbiani

Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice

Dec 5, 1998·Experimental Lung Research·L A OrtizM Friedman

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition

Sep 13, 2002·Chest·Robert VassalloCharles F Thomas

Lung injury linked to etanercept therapy

Nov 12, 2002·Chest·Laura Peno-GreenSteven Brantley

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

Jan 16, 2003·Arthritis and Rheumatism·Michael E WeinblattElliot K Chartash

Radiological versus histological diagnosis in UIP and NSIP: survival implications

Jan 30, 2003·Thorax·K R FlahertyF J Martinez

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

May 21, 2003·Annals of Internal Medicine·Hyon J KwonM Miles Braun

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

May 30, 2003·American Journal of Respiratory and Critical Care Medicine·Harold R CollardKevin K Brown

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends

Jun 7, 2003·American Journal of Respiratory and Critical Care Medicine·Panagiota I LatsiAthol U Wells

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

Jul 16, 2003·Annals of the Rheumatic Diseases·C TuressonE L Matteson

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

Mar 17, 2004·Circulation·Douglas L MannThomas Fleming

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

Apr 13, 2004·Arthritis and Rheumatism·R N MainiUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

The periodic safety update report as a pharmacovigilance tool

May 25, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael J Klepper

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

Jun 10, 2004·Arthritis and Rheumatism·Norihiro NishimotoTadamitsu Kishimoto

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Jun 18, 2004·The New England Journal of Medicine·Jonathan C W EdwardsTim Shaw

Diffuse idiopathic interstitial pneumonias. International multidisciplinary consensus classification by the American Thoracic Society and the European Respiratory Society, principal clinico-pathological entities, and diagnosis

Jun 24, 2004·Revue des maladies respiratoires·V CottinJ-F Cordier

United States Food and Drug Administration clinical trial of the Implantable Collamer Lens (ICL) for moderate to high myopia: three-year follow-up

Sep 8, 2004·Ophthalmology·Donald R SandersUNKNOWN ICL in Treatment of Myopia Study Group

Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis

Oct 2, 2004·The European Respiratory Journal·E BargagliP Rottoli

Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab

Nov 27, 2004·BMJ : British Medical Journal·Andrew J K OstorDavid G I Scott

Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification

Mar 26, 2005·Thorax·J J EganT Williams

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Dec 31, 2005·Arthritis and Rheumatism·Ferdinand C BreedveldGeorge T Spencer-Green

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial

Mar 31, 2006·Arthritis and Rheumatism·Désirée van der HeijdeUNKNOWN TEMPO Study Investigators

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

May 2, 2006·Arthritis and Rheumatism·Paul EmeryUNKNOWN DANCER Study Group

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

Mar 3, 2007·Annals of the Rheumatic Diseases·Gerd R BurmesterHartmut Kupper

A clinician's guide to the diagnosis and treatment of interstitial lung diseases

Jun 27, 2007·Southern Medical Journal·Sonye K DanoffMaureen R Horton

Rheumatoid arthritis treatment and the risk of severe interstitial lung disease

Jul 28, 2007·Scandinavian Journal of Rheumatology·F WolfeK Michaud

Update in diffuse parenchymal lung disease 2007

Mar 5, 2008·American Journal of Respiratory and Critical Care Medicine·Athol U Wells, Cory M Hogaboam

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Mar 25, 2008·Lancet·Josef S SmolenUNKNOWN OPTION Investigators

Interstitial lung disease in systemic sclerosis: a simple staging system

Mar 29, 2008·American Journal of Respiratory and Critical Care Medicine·Nicole S L GohAthol U Wells

Food and Drug Administration approval process for ophthalmic drugs in the US

Apr 15, 2008·Current Opinion in Ophthalmology·Rhea LloydWiley Chambers

The MRC breathlessness scale

Apr 29, 2008·Occupational Medicine·Chris Stenton

European biologicals registers: methodology, selected results and perspectives

Jul 24, 2008·Annals of the Rheumatic Diseases·A ZinkD P M Symmons

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial

Aug 2, 2008·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuSaeed Fatenejad

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Nov 4, 2008·Modern Rheumatology·Norihiro NishimotoTadamitsu Kishimoto

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

Nov 18, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Andrew BottomleyLily Claassens

Rituximab-induced lung disease: A systematic literature review

Jul 18, 2009·The European Respiratory Journal·H LiotéJ Cadranel

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Aug 12, 2009·Lancet·R F van VollenhovenJ Bratt

Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis

Sep 24, 2009·Rheumatology·Patricia MinnockBarry Bresnihan

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease

Dec 10, 2009·The European Respiratory Journal·E J KimH R Collard

Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.

Jan 12, 2010·Rheumatology International·Soo-Kyung ChoYoon-Kyoung Sung

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

Mar 3, 2010·The Journal of Rheumatology·Philip J MeaseAriella Kelman

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

May 7, 2010·Annals of the Rheumatic Diseases·W G DixonUNKNOWN British Society for Rheumatology Biologics Register

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis

May 15, 2010·Modern Rheumatology·Hayato YamazakiKenji Nagasaka

A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.

May 19, 2010·Rheumatology International·Shin-Ya KawashiriKatsumi Eguchi

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).

May 22, 2010·Annals of the Rheumatic Diseases·P EmeryH Tyrrell

Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis

Jun 1, 2010·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Cosmin DascaluSabiha Bandagi

FDA guidance on patient reported outcomes

Jun 23, 2010·BMJ : British Medical Journal·Jane Speight, Shalleen M Barendse

Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept

Jun 30, 2010·Modern Rheumatology·Hiroyuki SakaidaTamiko Takemura

❮ Previous

Next ❯

Citations

Adverse reactions to biologic agents and their medical management

Aug 13, 2014·Nature Reviews. Rheumatology·Onur BoymanFrançois Spertini

The role of biologics in treatment of connective tissue disease-associated interstitial lung disease

Jan 24, 2015·QJM : Monthly Journal of the Association of Physicians·C SharpH Adamali

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease

Jul 23, 2016·Clinical Rheumatology·Jorge A Zamora-LegoffEric L Matteson

Adverse effects of TNF inhibitors in SpA: are they different from RA?

Dec 10, 2014·Best Practice & Research. Clinical Rheumatology·Percival D Sampaio-Barros, Irene E van der Horst-Bruinsma

Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies

Jan 25, 2017·Expert Opinion on Biological Therapy·Juan ChenXiaoming Liu

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

Aug 16, 2017·Rheumatology and Therapy·James BluettDeborah P M Symmons

Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis

Dec 15, 2017·BioMed Research International·Alessia AlunnoFrancesco Carubbi

Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review

Dec 2, 2015·Therapeutic Advances in Musculoskeletal Disease·Kundan Iqbal, Clive Kelly

Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab

Sep 12, 2017·The Journal of Dermatology·Hideaki MiyachiHiroyuki Matsue

The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease

May 29, 2018·Arthritis & Rheumatology·Paolo SpagnoloVincent Cottin

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

Sep 29, 2017·RMD Open·Katie L DruceClive Kelly

Rheumatoid arthritis-associated lung disease

Mar 3, 2015·European Respiratory Review : an Official Journal of the European Respiratory Society·Megan ShawGanesh Raghu

Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis

Jun 3, 2015·Clinical Rheumatology·Kuttipurath Kandi Roshique, Vinod Ravindran

Humidifier disinfectant and use characteristics associated with lung injury in Korea

Jul 7, 2019·Indoor Air·Seung-Hun RyuSoo-Jong Hong

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?

Feb 23, 2019·Current Opinion in Rheumatology·Meghna JaniKimme Hyrich

Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report

Oct 27, 2015·BMC Pulmonary Medicine·Ho NamkoongTomoko Betsuyaku

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.

Aug 24, 2018·Rheumatology·Christopher R HolroydJo Ledingham

Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis.

Apr 10, 2019·Internal Medicine Journal·Annalisa FuiElena Bargagli

Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study

Jan 23, 2020·Journal of Clinical Medicine·Giulia CassoneMarco Sebastiani

Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study

Apr 14, 2016·Rheumatology International·Mitsuhiro AkiyamaTsutomu Takeuchi

Biologic Treatments in Interstitial Lung Diseases

Apr 2, 2019·Frontiers in Medicine·Theodoros KarampitsakosArgyris Tzouvelekis

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Apr 16, 2020·Journal of Clinical Medicine·Giulia CassoneMarco Sebastiani

Pulmonary involvement in rheumatoid arthritis

Mar 20, 2019·Zeitschrift für Rheumatologie·A Krause, A Rubbert-Roth

Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study

Nov 12, 2015·Arthritis Research & Therapy·Jeffrey R CurtisKathy L Schulman

Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre

Apr 27, 2017·Rheumatology·Md Yuzaiful Md YusofPaul Emery

Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.

Oct 30, 2019·Internal Medicine Journal·Andreina ManfrediMarco Sebastiani

Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Dec 8, 2020·Current Treatment Options in Rheumatology·Sicong HuangJeffrey A Sparks

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?

Apr 16, 2020·Respiratory Medicine Case Reports·Giulia CassoneAndreina Manfredi

Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends.

Apr 21, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Gurleen KourZabeer Ahmed

Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis

Jun 15, 2019·Clinical Therapeutics·Ruth CostelloMeghna Jani

Management of Connective Tissue Disease-Associated Interstitial Lung Disease.

May 25, 2021·Clinics in Chest Medicine·Leticia Kawano-Dourado, Joyce S Lee

Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

Jun 30, 2021·Joint, Bone, Spine : Revue Du Rhumatisme·Jacques MorelChristophe Richez

PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

May 17, 2021·Joint, Bone, Spine : Revue Du Rhumatisme·Jérémie SellamChristophe Richez

Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options.

Sep 6, 2020·Current Rheumatology Reviews·Daniel DejcmanValentin Sebastian Schäfer

❮ Previous

Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.